High-dose chemotherapy and autologous stem-cell transplantation in Korean patients with relapsed or refractory Hodgkin lymphoma

• Published in: International journal of hematology 2013-02, Vol.97 (2), p.256-262
• Main Authors: Park, Kwonoh, Yoon, Dok Hyun, Kim, Shin, Park, Chan-Sik, Huh, Jooryung, Lee, Sang-Wook, Suh, Cheolwon
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Female; Hematologic and hematopoietic diseases; Hematology; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation - adverse effects; Hodgkin Disease - diagnosis; Hodgkin Disease - mortality; Hodgkin Disease - therapy; Humans; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Neoplasm Staging; Oncology; Original Article; Recurrence; Remission Induction; Republic of Korea; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult
• ISSN: 0925-5710; 1865-3774
• DOI: 10.1007/s12185-013-1267-2

High-dose chemotherapy and autologous stem-cell transplantation (HDCT–ASCT) is a standard therapy for patients with relapsed or refractory Hodgkin lymphoma (HL). However, its efficacy in Asian patients has not been well investigated. A retrospective analysis of outcomes in 10 consecutive patients who underwent ASCT for HL in a single Korean centre from August 2005 to September 2010 was conducted. The median age was 34.5 years (range 17–64 years) and seven patients were male. Six patients were of stage III–IV at presentation. B symptoms were present in six patients. International Prognostic Score (IPS) was as follows: IPS = 1 ( n  = 5), IPS = 2 ( n  = 1), IPS = 4 ( n  = 2), and IPS = 5 ( n  = 2). The analysis included nine patients with relapsed HL and one primary refractory case. Four patients were in second complete response and the others were in partial response after salvage chemotherapy. With a median follow-up duration of 58.0 months, 3-year progression-free survival rate and overall survival rate from ASCT were 40 and 76 %, respectively. The results suggest that the efficacy of high-dose chemotherapy followed by ASCT in Korean patients with refractory or relapsed HL is comparable to that in Western patients.